- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02286063
Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) (AmbOx)
Randomized, Controlled Crossover Trial to Evaluate the Effects of Ambulatory Oxygen on Health Status in Patients With Fibrotic Lung Disease (FLD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The planned non-commercial study is a randomised, controlled crossover trial of ambulatory oxygen against no ambulatory oxygen over a four week period (two weeks on ambulatory oxygen and two weeks on air, with no portable devices), to evaluate the effects of ambulatory oxygen on health status in patients with ILD. A short crossover study in this context has many advantages, since ambulatory oxygen has immediate effect, with no wash-out period needed after use. The primary outcome of the study will be the change in health status, as measured by the K-BILD questionnaire (Thorax 2012 67: 804-810).
At the start of the trial, the effects of ambulatory oxygen on 6 Minute Walk Test (6MWT) parameters will be evaluated on oxygen and on air-filled canisters, with the patient blind to the contents of the canister, to assess whether oxygen-induced improvements in 6MWT parameters can predict its effectiveness in day to day life. The 6MWT is a well established and highly reproducible test validated in ILD patients, with significant prognostic implications.
The study design does not include a placebo arm because:
- The intervention is a combination of possible benefits from oxygen and the disadvantage of canister weight. These cannot be separated. Placebo control is impossible because there is no means of providing placebo weight. Attempts to control solely for oxygen use without taking canister weight into account are clinically meaningless. In a recent COPD, chronic obstructive pulmonary disease study, cylinder weight was reported as a barrier to use by 93% of study participants.
- A positive result against an air-filled canister arm would be clinically uninterpretable. This is a study design in which the 'placebo' would be actively harmful to study participants. Carriage of an air-filled cylinder would be expected to lead to earlier desaturation and reduced exercise tolerance. Such a design would not inform the real life comparison between oxygen plus cylinder and no intervention.
- All this aside, blinding is legally impossible (UK health and safety regulations require that oxygen cylinders for home use must be clearly labelled).
It should also be stressed that objective measures of change are evaluated as secondary end-points: the investigators expect to explore correlations between these variables and the primary end-point to exclude the possibility that an observed treatment benefit on the primary end-point might be confounded by a placebo effect.
A more in depth qualitative assessment of the impact of ambulatory oxygen will be undertaken via a semi-structured interview, in a subset of 20 patients, to investigate patients' and their carers' personal perspective on how the ambulatory oxygen has affected their day to day life. The interview will be conducted within 2 weeks of the end of treatment visit. Patients from the Royal Brompton Hospital site will be approached by the researcher at the end of treatment visit and asked if they will participate in the qualitative assessment. If the patient agrees a date will be agreed for the patient to be interviewed at a venue convenient to them (usually the patient's home).
During the interviews a semi-structured topic guide will address practical barriers to optimal oxygen usage, practical, social and psychological difficulties encountered, concerned about dependency, and views on the information required prior to ambulatory oxygen prescription. The interviews will also explore patients' (and carers') experience of participating in the trial. Notes will be written after each interview to aid reflective analytical processes. Individual feed back on how the system and the service could be improved will assess how the needs of patients and their future involvement can be incorporated into the design of more patients and their future involvement can be incorporated into the design of more patients centred devices.
Qualitative interview analysis: Interviews will be transcribed verbatim. Interview transcripts will be analysed thematically using a framework approach. Atlas/ti computer software (http://atlasti.com) will be used to manage and index the data prior to charting, mapping and interpretation.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW3 6NP
- Royal Brompton Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- IPF or another fibrotic ILD (including fibrotic NSIP, fibrotic organising pneumoni, and fibrotic hypersensitivity pneumonitis)
- patients aged 18 - 99 yrs
- Desaturation ≤ 88% on a 6MWT on room air
- Stable respiratory symptoms in the 4 weeks preceding the trial including the run in period
Exclusion Criteria:
- Patients meeting criteria for long term oxygen therapy, including hypercapnic patients
- Patients expected to change treatment during the course of the study
- Significant locomotor or communication difficulties and/or severe co-morbidities
- Patients with sarcoidosis or connective tissue disease affecting the musculoskeletal system
- Current smokers
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ambulatory oxygen cylinders
Subjects randomised to have the intervention of portable oxygen for the first two weeks.
Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized.
They will be a portable oxygen cylinder during 2 weeks when they realize activities.
|
The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb). Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm.
Other Names:
|
No Intervention: no oxygen cylinders
Subjects randomised to be on air for the first two weeks of the treatment period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in K-BILD The King's Brief Interstitial Lung Disease Questionnaire health status score
Time Frame: February 2017 (up to 3 years)
|
The mean change vs baseline in the K-BILD health status score on and off ambulatory oxygen will be compared by using either a paired t-test or Wilcoxon signed rank test, as appropriate to the distribution of the data.
To allow assessment of the effect of baseline values on treatment and any other potential confounders, regression with robust variances or linear mixed models will be used.
STATA software will be used for statistical analysis.
|
February 2017 (up to 3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dyspnoea scores
Time Frame: 2 weeks
|
assessed by the San Diego shortness of breath questionnaire.
|
2 weeks
|
Global assessment of change in walking ability and exertional breathlessness as better, the same or worse.
Time Frame: 2 weeks
|
2 weeks
|
|
Quality of life as assessed by SGRQ and the hospital anxiety and depression score
Time Frame: 2 weeks
|
2 weeks
|
|
Sense wear activity monitor measures of daily number of steps walked, daily expenditure and time spent at different levels of activity.
Time Frame: 1 week
|
1 week
|
|
Continuous oxygen saturation for 48 hours at weekly intervals
Time Frame: 48 hours
|
48 hours
|
|
Individual questions specifically related to activity from both the k-BILD and the SOBQ questionnaires
Time Frame: 2 weeks
|
2 weeks
|
|
Qualitative assessment of the impact of ambulatory oxygen
Time Frame: 2 weeks of treatment
|
semi-structured open-ended interviews in a subset of 20 patients and their carers
|
2 weeks of treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Elizabeth Renzoni, Dr, RB&HFT
Publications and helpful links
General Publications
- Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.
- Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013OE005B
- 2013-004355-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung; Disease, Fibroid (Chronic)
-
Sygehus LillebaeltDanmarks Lungeforening; Chiesi Foundation; Overlæge Jørgen Werner Schous og hustru...Active, not recruitingChronic Obstructive Pulmonary DiseaseDenmark
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Centre Hospitalier Intercommunal CreteilRecruitingChronic Obstructive Pulmonary Disease | Chronic Obstructive Lung DiseaseFrance
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Aveiro UniversityPrograma Operacional Inclusão Social e Emprego (POISE); Programa Operacional... and other collaboratorsCompletedLung Diseases | Chronic Obstructive Pulmonary Disease | Pulmonary Disease | Interstitial Lung Disease | Chronic Respiratory DiseasePortugal
-
Icahn School of Medicine at Mount SinaiUniversity of Pittsburgh; Brigham and Women's Hospital; University of New Mexico and other collaboratorsActive, not recruitingLung Cancer | Interstitial Lung Disease | Chronic Airway DiseaseUnited States
-
Beni-Suef UniversityCompleted
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Lung Disease (n=10) | Interstitial Lung Disease (n=10)Germany
-
King's College Hospital NHS TrustNot yet recruitingBronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Lung Cancer | Interstitial Lung Disease | Chronic Lung Disease | Dyspnea | Fibrotic Lung DiseaseUnited Kingdom
Clinical Trials on Ambulatory Oxygen
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Kuopio University HospitalHelsinki University Central Hospital; Tampere University HospitalActive, not recruitingPulmonary DiseaseFinland
-
University of SienaCompleted
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationNot yet recruitingFibrotic Interstitial Lung Disease
-
Aalborg University HospitalFisher and Paykel HealthcareCompleted
-
Taiho Pharmaceutical Co., Ltd.RecruitingDuchenne Muscular DystrophyJapan
-
Parc de Salut MarFundacion MAPFRECompleted
-
University of MichiganCompletedHypertensionUnited States
-
Apple Inc.CompletedAtrial Fibrillation | Arrhythmias, Cardiac | Atrial FlutterUnited States